Reimagining Medicine
Company overview
Financial review
2023 priorities
Appendix
Novartis delivers robust core operating income growth and core
margin expansion; achieves important innovation milestones
STRATEGY
Growth, cc
Group sales Q4 +3% (FY +4%)
IM sales Q4 +3% (FY +4%); US IM sales Q4 +7%
Sandoz sales Q4 +0% (FY +4%)
1
Innovation
Pluvicto EU approval for mCRPC post-taxane
Iptacopan Ph3 APPOINT-PNH met primary endpoint
Pluvicto Ph3 PSMAfore in mCRPC pre-taxane met primary endpoint
lanalumab Ph3 initiated in wAIHA; Ph3 initiating in 1L ITP and 2L ITP
3
Productivity, cc
Group core operating income Q4 +15% (FY +8%)
IM core operating income Q4 +14% (FY +8%)
IM core margin Q4 36.4%, +3.5%pts (FY 36.9%)
Sandoz core operating income Q4 -18% (FY -1%)
SG&A savings of ~USD 1.5bn to be fully embedded by 20242
2
ESG
4
Sustainability Linked Bond: Significant progress towards 2025 targets
Innovative Therapies in LMICS: ~1.2m patients; +26.3% vs. 2021
Novartis flagship programs: ~31m patients vs. 2025 target ~23m
Ratings: CDP - AA score¹; ATMI: Leaders group 10th consecutive year
Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 49 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY.
IM - Innovative Medicines division. mCRPC metastatic castration-resistant prostate cancer. WAIHA - warm autoimmune hemolytic anemia. ITP immune thrombocytopenia. LMIC low and middle income countries. CDP carbon
disclosure project. ATMI - Access to Medicine Index. 1. One of only two pharma companies with AA rating. 2. Relating to streamlined organizational model.
4 Investor Relations | Q4 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation